Dupixent® (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings

The use of Dupixent to treat EoE is investigational and has not been fully evaluated by any regulatory authority.